<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285255</url>
  </required_header>
  <id_info>
    <org_study_id>OFA</org_study_id>
    <nct_id>NCT04285255</nct_id>
  </id_info>
  <brief_title>Quality of Recovery Following Opioids Free Anaesthesia in Laparoscopic Sleeve Gastrectomy</brief_title>
  <official_title>Quality of Recovery of Opioid Free Anaesthesia Versus Opioids Anaesthesia Within Enhanced Recovery Protocol Following Laparoscopic Sleeve Gastrectomy in Saudi Arabia, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al Mashfa Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Al Mashfa Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopic sleeve gastrectomy is widely employed nowadays. Multimodal analgesia approach is
      implemented within the enhanced recovery protocol in our facility to improve participants'
      recovery. Due to side effects of narcotics, the may adversely affect the quality of recovery,
      the investigators intended to test the efficacy of opioids free anaesthesia on the quality of
      recovery and postoperative narcotic use.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>only the anaesthetist is one aware of the study groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of recovery 40 questionnaire (QoR-40)</measure>
    <time_frame>24 hours</time_frame>
    <description>postoperative quality of recovery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pethidine consumption</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical rating scale (NRS)</measure>
    <time_frame>24 hours</time_frame>
    <description>visual analogue scale postoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Narcotics</condition>
  <condition>Recovery Quality</condition>
  <condition>Analgesia</condition>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>Opioids anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received propofol-fentanyl induction of anaesthesia plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received preinduction with dexmeditomidine 0.1µg.kg-1 over 10 min. Induction with propofol 1.5 mg.kg-1-ketamine (ketofol 3:1 mixture) induction plus maintenance mixture of dexmedetomidine 0.5µg.kg-1.h-1, ketamine 0.5mg.kg-1.h-1, and lidocaine 1 mg.kg-1.h-1 plus ultrasound-guided Bilateral oblique subcostal TAP block using 20ml of bupivacaine hydrochloride 0.25% (Marcaine, Astra Zeneca UK) in each side (total volume of 40 ml) deposited equally on each side</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>opioids anaesthesia</description>
    <arm_group_label>Opioids anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>ketamine induction and analgesia as opioids free anaesthesia versus opioids analgesia</description>
    <arm_group_label>OFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Injection [Precedex]</intervention_name>
    <description>alpha 2 agonist with sedative, analgesic effect</description>
    <arm_group_label>OFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oblique subcostal transversus abdominis plane block</intervention_name>
    <description>Bupivacaine 0.25% injected under ultrasound usage in the transversus abdominis plane</description>
    <arm_group_label>OFA</arm_group_label>
    <arm_group_label>Opioids anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>infusion of lidocaine 2%(1mg/kg/h)</description>
    <arm_group_label>OFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  70 ASA II - III adult patients (18-60 years old)

          -  Elective laparoscopic bariatric surgery.

          -  Body mass index (BMI) is from 40 to 60

          -  Trocar sites at or above the umbilicus (T 10 dermatome).

        Exclusion Criteria:

          -  Allergy to amino-amide local anaesthetics,

          -  presence of coagulopathy

          -  local skin infection at injection sites,

          -  preoperative chronic dependence upon opioid and NSAID medications,

          -  liver or renal insufficiency,

          -  history of psychiatric or neurological disease, deafness,

          -  previous open surgery,

          -  patients who need to be converted to open surgery with more tissue trauma,

          -  ASA (American society of anesthesiologists) class above III were excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohamed I Elsayed, MD</last_name>
    <phone>966596172277</phone>
    <email>mibrahim72@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Al Mashfa medical center</name>
      <address>
        <city>Khobar</city>
        <state>Eastern Provence</state>
        <zip>34225/7564</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed I Elsayed, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 22, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

